RNS Number : 6587M

Fusion Antibodies PLC

22 January 2021

Fusion Antibodies plc

("Fusion" or the "Company")

Director/PDMR Shareholding

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been notified that, Richard Buick, Chief Technical Officer of the Company, has today sold 8,875 ordinary shares in the Company ("Ordinary Shares") a price of 124.2 pence per Ordinary Share. Following this sale, Richard Buick holds 486,250 Ordinary Shares, representing approximately 1.91 per cent. of the Company's issued share capital.

The following notification, made in accordance with the requirements of the UK Market Abuse Regulation, gives further details.

 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                        Richard Buick 
     --------------------------  ---------------------------------------------- 
 2    Reason for the notification 
 a)   Position/status             Chief Technical Officer 
     --------------------------  ---------------------------------------------- 
 b)   Initial notification        Initial notification 
     --------------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
 a)   Name                        Fusion Antibodies plc 
     --------------------------  ---------------------------------------------- 
 b)   LEI                         213800KBAYRC9VOQ9V39 
     --------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
 a)   Description of the          Ordinary shares of 4p each in Fusion 
       financial instrument,       Antibodies plc 
       type of instrument          Identification code (ISIN) for Fusion 
       Identification code         Antibodies plc ordinary shares: GB00BDQZGK16 
     --------------------------  ---------------------------------------------- 
 b)   Nature of the transaction   Sale of shares 
     --------------------------  ---------------------------------------------- 
 c)   Price(s) and volume(s)        Price(s)   Volume(s) 
                                     124.2p     8,875 
     --------------------------  ---------------------------------------------- 
 d)   Aggregated information      N/A 
       - Aggregated volume 
       - Price 
     --------------------------  ---------------------------------------------- 
 e)   Date of the transaction     22 January 2021 
     --------------------------  ---------------------------------------------- 
 f)   Place of the transaction    London Stock Exchange, XLON 
     --------------------------  ---------------------------------------------- 


 Fusion Antibodies plc                                                  www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                                           Via Walbrook PR 
 James Fair, Chief Financial Officer 
 Allenby Capital Limited                                                Tel: +44 (0)20 3328 5656 
 James Reeve / Asha Chotai (Corporate 
 Tony Quirke (Sales and Corporate Broking) 
 Walbrook PR                                   Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com 
 Anna Dunphy                                                            Mob: +44 (0)7876 741 001 
 Paul McManus                                                           Mob: +44 (0)7980 541 893 

About Fusion Antibodies plc

Fusion is a Belfast based biotechnology company providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

Fusion is a Collaborative Research Organisation (CRO) which provides antibody discovery, engineering and supply, through to cell line development. At every stage, our client's vision is central to how we work, ensuring the best molecule goes to the clinic. Our world-class humanization and antibody optimization platforms harness the power of the natural diversity of antibodies. To address remaining market needs in antibody discovery, Fusion is creating a fully human antibody library to capture the entire human antibody repertoire.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $95.5 billion in 2017 and is forecast to surpass $174.2 billion in 2026, an increase at a CAGR of 6.9 per cent. for the period 2018 to 2026. In 2018, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $62 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 22, 2021 10:37 ET (15:37 GMT)